377 related articles for article (PubMed ID: 34509860)
1. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Evaluation of a Series of 1,5-Diaryl-1,2,3-triazole-4-carbohydrazones as Inhibitors of the YAP-TAZ/TEAD Complex.
Gibault F; Sturbaut M; Coevoet M; Pugnière M; Burtscher A; Allemand F; Melnyk P; Hong W; Rubin BP; Pobbati AV; Guichou JF; Cotelle P; Bailly F
ChemMedChem; 2021 Sep; 16(18):2823-2844. PubMed ID: 34032019
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
Mills KR; Misra J; Torabifard H
J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
[TBL] [Abstract][Full Text] [Related]
4. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
5. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
6. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
7. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
[TBL] [Abstract][Full Text] [Related]
8. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
Zagiel B; Melnyk P; Cotelle P
Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
[TBL] [Abstract][Full Text] [Related]
9. Development of LM98, a Small-Molecule TEAD Inhibitor Derived from Flufenamic Acid.
Mélin L; Abdullayev S; Fnaiche A; Vu V; González Suárez N; Zeng H; Szewczyk MM; Li F; Senisterra G; Allali-Hassani A; Chau I; Dong A; Woo S; Annabi B; Halabelian L; LaPlante SR; Vedadi M; Barsyte-Lovejoy D; Santhakumar V; Gagnon A
ChemMedChem; 2021 Oct; 16(19):2982-3002. PubMed ID: 34164919
[TBL] [Abstract][Full Text] [Related]
10. Mechanosignaling YAP/TAZ-TEAD Axis Regulates the Immunomodulatory Properties of Mesenchymal Stem Cells.
Yoshii H; Kajiya M; Yoshino M; Morimoto S; Horikoshi S; Tari M; Motoike S; Iwata T; Ouhara K; Ando T; Yoshimoto T; Shintani T; Mizuno N
Stem Cell Rev Rep; 2024 Jan; 20(1):347-361. PubMed ID: 37917410
[TBL] [Abstract][Full Text] [Related]
11. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
14. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
15. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
17. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
[TBL] [Abstract][Full Text] [Related]
18. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
19. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]